Magnesium for Peroral Endoscopic Myotomy

NCT ID: NCT04638881

Last Updated: 2024-05-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-28

Study Completion Date

2023-04-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Postoperative pain after peroral endoscopic myotomy occurs due to involuntary esophageal smooth muscle spasms. Magnesium has antispasmodic properties as a smooth muscle relaxant. This study hypothesizes that among patients having peroral endoscopic myotomy, magnesium will decrease postoperative esophgeal pain as measured by the esophageal symptoms questionnaire, while decreasing perioperative opioid requirements.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Spasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion

Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.

Group Type EXPERIMENTAL

Magnesium sulfate

Intervention Type DRUG

Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.

Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion

Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type DRUG

Placebo. Bolus and infusion administered similarly under general anesthesia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium sulfate

Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.

Intervention Type DRUG

Normal Saline

Placebo. Bolus and infusion administered similarly under general anesthesia.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Planned peroral endoscopic myotomy procedure

Exclusion Criteria

* cannot give consent
* patients who are clinically unstable and/or require urgent/emergent intervention
* previous esophageal myotomy
* preexisting hypermagnesemia
* end-stage renal disease
* neuromuscular disease, including but not limited to Guillain-Barre syndrome, myasthenia gravis, congenital myopathy, and muscular dystrophy
* preexisting heart failure
* severe ventricular systolic dysfunction (left or right ventricle)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Richard K. Kim

Clinical Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard K Kim, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Joo H Hwang, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Ban C Tsui, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford Health Care

Stanford, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

58859

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MSG and Gastrointestinal Motility
NCT01009658 COMPLETED NA
Effect of Zinc on Barrett's Metaplasia
NCT01984580 UNKNOWN PHASE1